Viropharma — Investor Day (September 2012)
167 slides from Viropharma's investor day presentation, Sep 21, 2012
Slide 1: Broadening Horizons: 2012 Investor Day
Broadening Horizons 2012 ViroPharma Incorporated Investor Day September 21, 2012
Slide 2: Introduction
Introduction Vincent Milano Chief Executive Officer 2
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements, including statements regarding our financial guidance for 2012 and beyond, our projected financial condition, the rate of future growth and the development and commercialization status and prospects of certain of our products and product
Slide 4: The ViroPharma Story
The ViroPharma Story 4 PEOPLE PATIENTS PHYSICIANS EMPLOYEES SHAREHOLDERS GROWTH DIVERSIFICATION EXECUTION UPSIDE Providing Hope for People Suffering from Rare & Life-Threatening Diseases
Slide 5: Today's Agenda
Today’s Agenda North American Operations EU Commercial Operations 15 Minute Break Approximately 10:15 – 10:30 AM C1-INH Potential Therapeutic Uses Subcutaneous Cinryze® Maribavir VP-20621 NTCD Capital Structure and Long-Range Model Meeting Adjourned – Approximately 12:45 PM
Slide 6: North American Operations
North American Operations Paul Firuta Vice President & General Manager, Americas 6
Slide 7: Goals and Objectives
Goals and Objectives 7 N.A. Peak Revenue >$600 Million (IV/HAE Only) Cinryze® Post Orphan Exclusivity Base Cinryze Business Competitive Landscape
Slide 8: Agenda
Agenda 8 Cinryze® Brand Strategies and Performance Customer Insights Review Changes in Competitive Landscape Cinryze IV—Post Orphan Exclusivity Geographic Expansion
Slide 9: Strategic Objectives in HAE Market
Strategic Objectives in HAE Market Raise awareness of the severity and impact of HAE amongst allergists and other targeted HAE-treating specialists Increase diagnosis rate of HAE Educate clinicians and patients about the benefits of prevention and establish Cinryze as the preferred prophylactic ther
Slide 10: Increase Diagnosis: Accomplishments
Increase Diagnosis (Dx): Accomplishments 10 A. ViroPharma 2012 Market Research 100% growth in Dx 2006 to 2012 Estimated over 7,000 Dx patients in North America CinryzeSolutions™ known patient population >1,700 60% Rx are Allergy / Immunology 40% other specialties 60% Rx in CinryzeSolutions coming fr
Slide 11: Increase Enrollment: Accomplishments
Ended Q2/12 maintaining >820 patients @ 1.8 doses per week Approximately 1/3 of patients who initiated Cinryze therapy in 2012 have been diagnosed in last 3 years 3rd quarter 2012 is the 2nd largest Rx quarter since Q3 2009 Increase Enrollment: Accomplishments Cinryze® Sales Force & CinryzeSolutions
Slide 12: Maintain Patients On Therapy: Accomplishments
Maintain Patients On Therapy: Accomplishments 12 Less than 5% of patients discontinue Cinryze® prophylactic therapy 78% of patients infuse in home 88% satisfaction with CinryzeSolutions program 94% satisfaction with CinryzeSolutions™ Care Coordinator CinryzeSolutions Patient Service Center Focused o
Slide 13: Growth in Expected North America Peak Sales
>$600 million North America $450 million peak sales 2 years ago Execution Has Delivered Progressive Growth in Expected Peak Sales 13 Strategies and tactics performance exceed expectations Significant opportunity still exists in Allergy / Immunology and other specialties Key areas of focus for Commer
Slide 14: CinryzeSolutions Programs
14 CinryzeSolutions™ Programs
Slide 15: CinryzeSolutions Programs
Access, resources, and support every step of the way CinryzeSolutions™ Programs 15
Slide 16: Customer Insights
Customer Insights Better Understanding of the Market 16
Slide 17: Physician Reported Findings 2012
Physician Reported Findings 2012 17 More than 50% of Allg/Immun surveyed intend to increase utilization of Cinryze® Significant decrease in physician satisfaction with anabolic steroids and FFP Physicians across all specialties are highly satisfied with Cinryze for prophylactic treatment No reported
Slide 18: Physician Reported Findings 2012
Physician Reported Findings 2012 18 Anabolic steroids and FFP are 71% more likely to be prescribed in other specialties Allg/Immun still likely to prescribe anabolic steroids 33% of the time Cinryze® is now more likely be prescribed than anabolic steroids in Allg/Immun Significant progress in Allg/I
Slide 19: Months of Consistent Rx Generation
35 Months of Consistent Rx Generation Post Launch Phase 19 B. ViroPharma Inc. CINRYZESolution Database August 28, 2012 Months Number of SRF’s
Slide 20: Key Market Factors
Key Market Factors 20 Recent clinical experience with danazol is not as favorable from an efficacy perspective Increased awareness regarding risk of long-term safety issues with danazol Increasing awareness of newer treatment options A. ViroPharma 2012 Market Research
Slide 21: Competitive Landscape Changing
Competitive Landscape Changing 21
Slide 22: New Treatment Guidelines
New Treatment Guidelines Attenuated androgens and C1-INH should be considered for routine prevention in HAE patients with > 1 – 2 attacks/month Attenuated androgens are not identified as first-line therapy Maximum recommended daily dose for danazol = 200 mg/day Attenuated androgens are not recommend
Slide 23: Key Take Away: Competitive Landscape
Key Take Away: Competitive Landscape 25 Efficacy of danazol is beginning to be questioned Adherence to the new clinical treatment guidelines would clearly limit the use of anabolic steroids Cinryze® is well positioned as a safe and efficacious prophylactic therapy Opportunity to educate managed care
Slide 24: Post Cinryze IV Orphan Exclusivity October 2015
Post Cinryze® IV Orphan Exclusivity October 2015 26
Slide 25: The Exclusivity Proposition
The Exclusivity Proposition 27 Orphan Market Exclusivity 7 Years +5 Years HCR Data Exclusivity US 2008 2020 2015 Today
Slide 26: Low Risk of 2nd Approved IV C1-INH Prophylactic
Low Risk of 2nd Approved IV C1-INH Prophylactic Indication 2015 to 2020 2nd approved IV C1-INH Prophylaxis HAE Therapy Post-2015 Ethical Issues with Trial Design Patient Recruitment will be Challenging Phase III Double Blinded Placebo Controlled Trial No CI Indicating Phase III Trial for IV Prophyla
Slide 27: Ultra Orphan Drug Market Analog: Alpha-1 Antitrypsin
Market Background and Data Ultra Orphan Drug Market Analog Alpha-1 Antitrypsin 29 Key Insights The 1st entrant in class maintaining the market value leadership despite one competitor with better profile The originator product sales grew year-over-year post exclusivity period Total market value incre
Slide 28: Key Take Away
Key Take Away 30 Low risk of a new IV C1-INH prophylactic entrant post Cinryze® Orphan Exclusivity Key to maintaining our position in the market is: Patient Service Model – CinryzeSolutions™ Based on Alpha-1 market analog: Alpha-1 market grew Innovator product maintained revenue Innovator product co
Slide 29: Geographic Expansion
Geographic Expansion 31
Slide 30: Other Geographic Market Opportunities
Other Geographic Market Opportunities 32 Canada – filed and has a Priority Review Anticipated regulatory decision in Q4 2012 Market is estimated to be 1/10th of US Market opportunity will depend on pricing Latin America Evaluating markets Working with KOLs and potential distribution partners to unde
Slide 31: Closing Remarks North America
Closing Remarks 33 North America Peak Revenue $600 million + IV / HAE Only Deliver consistent patient enrollment & outstanding patient services Implement new consensus treatment guidelines Low risk of a 2nd IV C1-INH post Orphan Exclusivity Expansion into other geographies Subcutaneous formulation O
Slide 32: To the Makers of Cinryze
To the Makers of Cinryze, To the owners, operators, employees, producers and everybody who has anything to do with the production of CINRYZE, I have no words that can express my gratitude for the care that has been given to me in the past 6 months. I’ve had only one minor HAE attack after starting C
Slide 33: ViroPharma in Europe
ViroPharma in Europe Thierry Darcis, MD Vice President & General Manager, Europe 35
Slide 34: ViroPharma Europe in a Nutshell
ViroPharma Europe in a Nutshell 36 One Team Three Launched Brands Delivering Innovative Disease Management Solutions
Slide 35: ViroPharma Europe – It All Fits Together
ViroPharma Europe – It All Fits Together Serious, debilitating diseases Clear medical needs Overlooked markets Lagging in innovation Established therapeutic areas Vying for market share Products which make a difference for patients Introducing new “gold standards” Highly specialized markets Competin
Slide 36: ViroPharma Europe – How We Deliver
ViroPharma Europe – How We Deliver Deep understanding of Disease Health care providers Patients and carers Developing meaningful insights on Treatment paradigms “Disease community” Selecting the highest medical need segments Including relevant stakeholders Deploying 2 key initiatives at a time Scien
Slide 37: Is the Model Working?
ViroPharma Europe – Is the Model Working? 39 Launched Cinryze® in October 2011; Buccolam® in December 2011; Plenadren® in September 2012 Cinryze – Over 60 patients on long term prevention / treatment on demand Buccolam – ~50% of Primary Care Trusts in UK are switching over to Buccolam. Positive opin
Slide 38: European Roll-Out of Cinryze
European Roll-Out of Cinryze 40 This presentation includes information about a product which is approved for indications in Europe which are not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It is intended t
Slide 39: HAE in Europe—An Established Market
HAE in Europe—An Established Market 41 Overall epidemiology similar to that of the US (~12,500 patients) Differences exist at individual country level: Awareness, diagnosis rates, and treatment approaches HAE management by health care structures Treating specialists Current paradigm is still acute t
Slide 40: HAE in Europe Prior to Cinryze: Burden of Illness
HAE in Europe Prior to Cinryze® Burden of Illness Study Confirms Needs and Paradigm 42 First multi-country, cross-sectional survey completed by patients partnered with KOLs and advocacy groups Excitement in the HAE community (KOLs and advocacy groups) 59% of patients had >1 attack/month The majority
Slide 41: HAE in Europe—Burden of Illness Study
HAE in Europe—Burden of Illness Study Confirms Needs and Paradigm 43 Overall impact (0 lowest; 10 highest) Daily life is impacted regardless of attack location Patients experience substantial detriments in career and educational advancement due to HAE EAACI Geneva 2012
Slide 42: HAE Prevention – Limited Prophylactic Competition in Europe
HAE Prevention – Limited Prophylactic Competition in Europe 44 Product Company Acute Prevention Use in HAE Prevention ( ) Cinryze® ViroPharma ? ? Only C1-INH product approved for a Prevention indication in EU Berinert CSL-B ? X Prevention not in label; has not been studiedUsed as treatment on demand
Slide 43: HAE Acute Therapies—A Highly Competitive Market
HAE Acute Therapies—A Highly Competitive Market 45 Product Company Acute Prevention EU Regulatory Status Cinryze® ViroPharma ? ? Central EMA approval Berinert CSL-B ? X Approved in Europe through Mutual Recognition Program Firazyr Shire ? X Centrally approved by EMA Pan-EU launch in 2009 Rhucin Phar
Slide 44: HAE Prevention – The Future of HAE in Europe
HAE Prevention – The Future of HAE in Europe 46 Prevention of HAE attacks is more established than commonly thought 30% to 60% of current patients managed by prevention Until Cinryze® launch, the main “prophylactic products” included: Androgens (danazol) Tranexamic acid With Cinryze launch, preventi
Slide 45: Cinryze—The European Product has Passed Major Hurdles
Cinryze®—The European Product has Passed Major Hurdles 47 Obtained EMA centralized approval in June 2011 with broad label Switzerland – Final stages of the regulatory process Launched and reimbursed in: Germany, Spain; UK; Denmark; Iceland Average ex-factory price per dose ca. € 1,400, in line with
Slide 46: Geographical Rollout of Cinryze
Geographical Rollout of Cinryze® 48 Austria (2013) Czech Rep. (2013) Denmark France Germany Hungary (2013) Iceland Ireland Italy (2013) Norway Spain Sweden Switzerland (2013) UK Belgium & Netherlands (via Sanquin) Israel (2013) Austria Czech Rep. Denmark Germany Greece Hungary Ireland Italy Norway P
Slide 47: 2010 Rollout Strategy
2010 Rollout Strategy—The Original Strategy Remains Valid 49 Patient visits GP / A&E to discuss symptoms Patient takes the drug Origination Diagnosis Treatment Choice Brand Choice 1st Administration Compliance Persistence Patient complies with prescription Patient does not comply with prescription H
Slide 48: Choosing Cinryze in Europe
Choosing Cinryze® in Europe First priority of rollout: Switch prescribers from Berinert, danazol and tranexamic acid to Cinryze for preventative HAE management 50 1 Capture market share “own the prevention market” $3.1M net sales in first half of 2012 More than 60 patients in Europe have started Cin
Slide 49: Preventative HAE Management as Gold Standard
Preventative HAE Management as Gold Standard The second priority of the Cinryze® rollout will be to firmly establish the concept of preventative HAE management 51 2 “The ability to prevent attacks can provide relief to many patients” (Dr. Emel Aygören^Pürsün) “Routine prevention can help to improve
Slide 50: Encouraging Compliance
Encouraging Compliance The third priority of the Cinryze® rollout will be to make using the product as convenient as possible for the patient, including future development of subcutaneous formulation 52 3 Libertas+ (homecare services similar to US Ryze Above®) successfully rolled-out in Germany and
Slide 51: Cinryze—One-Stop Shop Solution for HAE Management
Cinryze®—Possibility of a One-Stop Shop Solution for HAE Management in Europe HAE epidemiology similar to that of US Prior prevention options not satisfying patient needs Cinryze is the only HAE product with a broad label including acute and preventative label and self-administration Cinryze has the
Slide 52: European Launch of Plenadren
European Launch of Plenadren® Dirk De Rijdt Director & Brand Leader, Europe 54 This presentation includes information about a product which is not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It is intended
Slide 53: Adrenal Insufficiency—Disease & Epidemiology in Europe
Adrenal Insufficiency—Disease & Epidemiology in Europe Adrenal Insufficiency (AI) is an Orphan Disease affecting ~ 400 patients per million inhabitants (range 80,000 – 167,000 pts in EU) Adrenal Insufficiency has two main causes: Primary AI – Addison’s Disease Secondary AI – associated with hypopitu
Slide 54: Glucocorticoid Replacement – Competition Products
AI in Europe—Glucocorticoid Replacement – Competition Products 56 Currently branded products account for 26% of the market, with generic products accounting for the remaining 74% As many of the branded products were launched over 40 years ago, they are now priced and treated as generic products Prod
Slide 55: Adrenal Insufficiency – Significant Unmet Need
57 Adrenal Insufficiency – Significant Unmet Need
Slide 56: The Circadian Rhythm—Un-physiological Timing and Dose of HC
The Circadian Rhythm—The Un-physiological Timing and Dose of HC 58 Johannsson et al. J Clin Endocrinol Metab. 2012;97:473-81 1.Plat et al. 1999; 2.Gangwisch 2009; 3. Matthews et al. 2006 4. Garcia-Borreguero et al. 2000; 5. Vgontzas et al. 2001 Clock time 08.00 12.00 16.00 24.00 0 200 400 600 800 Co
Slide 57: Plenadren—Immediate and Extended Release Action
Plenadren®—Immediate and Extended Release Action 59 Rapid release part together with controlled release part mimics diurnal variation Night time cortisol-free interval Reproducible absorption and high bioavailability Once-daily administration Two strengths: 20mg and 5mg Plenadren’s “dual action” ach
Slide 58: Plenadren vs. HC (TID)—Clinical Program Conclusions
Plenadren® vs. HC (TID)—Conclusions from the Clinical Program 60 Plenadren resulted in: Increased cortisol exposure during the first hours after intake in the morning Reduced exposure in the afternoon and evening, avoiding the last two peaks during TID Reduced total exposure over the 24-hour period
Slide 59: Plenadren—In Summary
Plenadren®—In Summary 61 Since ViroPharma’s acquisition of Plenadren: Manufacturing to meet 24-36 month demand in place Shelf-life increased to 36 months Dedicated commercial capabilities built in preparation for launches P&R filings and launches in further countries under preparation Average price
Slide 60: Plenadren—Rollout Strategy
Plenadren®—Rollout Strategy 62 Patient visits GP to discuss symptoms Patient is satisfied Origination Diagnosis Treatment Choice Brand Choice Routine Follow-up Visits Long-term Persistence Endocrinologist chooses between natural or synthetic products Patient is not satisfied Endocrinologist diagnose
Slide 61: Switching Patients with Unmet Needs
1 Switching Patients with Unmet Needs First priority of Plenadren® rollout: Switch patients with poor disease and metabolic control and issues with compliance during conventional treatment 40% to 60% of currently treated primary and secondary AI patients are not well controlled or have difficulties
Slide 62: Achieving Short-term Persistence
Achieving Short-term Persistence Plenadren’s® success depends on improving treatment habits; clear guidance to physicians, nurses, and patients; better patient-physicians interactions; and patient education Plenadren offers the opportunity of improved compliance and better management during episodes
Slide 63: Circadian Glucocorticoid Replacement as 1st Choice
“Circadian” Glucocorticoid Replacement as 1st Choice Treatment for AI patients Through the initial use of Plenadren® in high medical need patients, health care providers supported by patient associations will gain experience and confidence to use Plenadren in a broader AI population, including newly
Slide 64: Plenadren—Can Become the Gold Standard Treatment of AI
Plenadren®—Can Become the Gold Standard Treatment of AI AI is a serious disease characterized by increased mortality in the short (adrenal crisis) and long-term (metabolic consequences); difficult to manage by patients and physicians Plenadren has been designed to better mimic the normal physiologic
Slide 65: European Roll-Out of Buccolam
European Roll-Out of Buccolam® Arun Mistry, MD Senior Director, Medical Affairs Europe 67 This presentation includes information about a product which is not approved in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It
Slide 66: Convulsive Seizures—Disease & Epidemiology in Europe
Causes and clinical manifestations Convulsive Seizures (CS)—Disease & Epidemiology in Europe 68 Genetic predisposition Acquired brain damage Increased risk of attacks Epilepsy Abnormal and excessive brain neuron discharge Unspecific provoking factors Specific provoking factors Altered consciousness
Slide 67: CS—The Most Common Serious Brain Disorder
CS—The Most Common Serious Brain Disorder 69 Epilepsy: 5% of people can expect ? 1 seizure during lifetime In Europe an estimated 700,000 suffers from this condition between 3 months and less than 18 years of age Important to manage both acute and chronic elements of epilepsy A well-know condition P
Slide 68: CS in Europe—Available Products
CS in Europe—Available Products 70 Generic name Route of administration Dosage Available for clinical use Diazepam Rectal 0.2-0.5 mg/kg Licensed in most countries (eg. Stesolid® in Spain, Miconoan® in Italy) Midazolam (hydrochloride) Buccal Age-specific dosing EU-wide license (Buccolam®) Midazolam (
Slide 69: Acute Management of CS—An Overlooked Medical Need
Acute Management of CS—An Important, Overlooked Medical Need 71 ViroPharma’s “PERFECT Initiative” has highlighted many of these issues While research has focused on the chronic treatment of CS, acute management of the condition has not evolved in decades and still relies on IRD (Intra Rectal Diazepa
Slide 70: PERFECT Initiative
PERFECT is a ViroPharma-funded initiative, guided by a steering committee of leading clinical experts and patients associations 72 “What happens when a child or adolescent has a prolonged, acute, convulsive seizure in the community?”
Slide 71: Preliminary Conclusions
Preliminary Conclusions 73 IRD fails community and carers. Acute management of CS requires a different and more convenient benzodiazepine
Slide 72: Buccolam – 1st Product Approved Through EMA PUMA
Buccolam® – 1st Product Approved Through the EMA “PUMA” (2011) 74 4 age-specific unit-dose pre-filled oral syringes (4 tubes per carton) Single dose for simplified management by carer Buccolam vs. IRD Several clinical studies have investigated the efficacy and safety of buccal midazolam Conclusions
Slide 73: Buccolam – Rollout Strategy
Buccolam® – Rollout Strategy 75 Patient visits GP/Emergency Care/Neurologist after first seizure Patient/Parent is satisfied Origination Diagnosis Treatment Choice Brand Choice Routine follow-up visits Long-term Persistence Neurologist chooses between no acute management (majority) or IRD (mostly),
Slide 74: Build Buccolam as Gold Standard for Acute CS Management
Build Buccolam® as Gold Standard for Acute CS Management Adoption by the reference centers KOL advocacy is critical to the conversion to Buccolam from other treatments Focus on the top 5-10% of accounts in each market Buccolam listed in formularies and used in hospital and for out-patients Drive the
Slide 75: Switch Patients with Unmet Needs
Switch Patients with Unmet Needs Utilize advocates from reference centers to educate physicians closest to patients on available acute seizure treatment options Work closely with patient advocacy groups to provide education on management of acute CS Add Buccolam to chronic therapy plan as acute seiz
Slide 76: Buccolam – In Summary
Buccolam® – In Summary Obtained EMA centralized approval in September 2011 Launched and reimbursed in UK and Germany; NPP availability in France and Spain Obtained an average ex-factory price per carton of ~€83 $1.8 M net sales in first half of 2012 Pricing & reimbursement process on-going in furthe
Slide 77: Buccolam – Potential Standard of Care for Acute CS
Buccolam® – Has Potential to be Standard of Care for Acute Management of CS Patients, carers, and doctors are not satisfied with the current acute seizure management practices and current IRD solution Buccolam unique profile meets clinical and social needs of patients and carers Buccolam is cost-sav
Slide 78: ViroPharma Europe – Conclusions
ViroPharma Europe – Conclusions 80 Differentiated brands Bringing innovation to patients and carers Exciting products for patients, physicians, and ViroPharma Peak potential: $300-500 million Focused on customers Superior commercialization capabilities Broad geographical reach Scalable
Slide 79: Break
15 Minute Break Refreshments and Snacks Please Return to Reconvene at 10:45 AM 81
Slide 80: C1 Inhibitor: Potential New Therapeutic Uses
C1 Inhibitor: Potential New Therapeutic Uses Jeffrey M. Dayno, MD Vice President, Global Medical Affairs 82
Slide 81: The Opportunity
The Opportunity Life cycle management: maximizing the value of the C1 Inhibitor franchise through new data and new indications C1 Inhibitor: platform development opportunity Greater understanding of the evolving science Intersection of the science and commercial opportunities Update on progress to d
Slide 82: Identifying New Clinical Targets
Identifying New Clinical Targets 84 Patient populations C1-INH MOA Disease pathophysiology
Slide 83: Life Cycle Management
Life Cycle Management 85 Unmet Medical Need Commercial Opportunity Product Profile
Slide 84: Mechanism of Action of C1 Inhibitor
Mechanism of Action of C1 Inhibitor 86 Biochemical function Biological effect Potential therapeutic effect Inhibition of C1r, C1s, MASPs Inhibition complement activation Anti-inflammatory Inhibition of factor XIIa and kallikrein Inhibition contact activation Anti-inflammatory Inhibition of factor XI
Slide 85: Diseases Involving the Complement System
Diseases Involving the Complement System 87 Ricklin D and Lambris JD. 2007
Slide 86: Current Approach
Current Approach 88 Refined thinking regarding potential clinical targets Informed by pre-clinical data from current Investigator Initiated Studies (IIS) Ongoing discussions with experts in Complement research Engagement with clinical opinion leaders in various medical subspecialties Prioritizing op
Slide 87: Goals of an IIS Program
Goals of an IIS Program 89 Provide a mechanism to support independent, investigator initiated research to: Advance clinical knowledge of different disease states, patient populations Further the understanding of the efficacy & safety of a therapeutic product in these disease states & patient populat
Slide 88: Current Preclinical IIS Studies
Current Preclinical IIS Studies 90 Study Status Experimental Autoimmune Encephalomyelitis (EAE): mouse model of Multiple Sclerosis Cardiff University Phase 1 (acute EAE) completed; beginning Phase 2 study (chronic EAE) Model of Type 1 Diabetes MellitusBIDMC Harvard Project 70% completed – anticipate
Slide 89: Acute EAE: Preliminary Data
Acute EAE: Preliminary Data 91 * * Treatment Regimen: 0.2ml of 100U/ml (32mg/ml) SC on alternate days, from day 8 With permission, Paul Morgan, Cardiff University
Slide 90: Liver IRI: Preliminary Data
Liver IRI: Preliminary Data Mouse model of liver ischemia reperfusion injury in setting of tumor resection, transplantation Hepatic artery clamped for 30 minutes 5 minutes prior to reperfusion Cinryze® administered vs. placebo (control) Results (at 24 hours): Control mice: ALT (liver function enzyme
Slide 91: Cinryze Inhibits All Pathways of Complement Activation
Cinryze: Inhibits All 3 Pathways of Complement Activation PNH others Ischemia Reperfusion Antibody Diseases ViroPharma, data on file
Slide 92: C1-INH IIS Strategic Framework
C1-INH IIS Strategic Framework Neuroimmunology Neuromyelitis Optica (NMO; Devic’s Syndrome) Myasthenia Gravis Guillain-Barré disease (AIDP); CIDP Multiple Sclerosis Hematologic diseases Autoimmune Hemolytic Anemia (AIHA) Paroxysmal Nocturnal Hemoglobinuria (PNH) Hemolytic Uremic Syndrome (HUS) Angio
Slide 93: Current Clinical IIS Studies
Current Clinical IIS Studies 95 Study Status RNAi markers in HAEJohns Hopkins Subject recruitment; blood sample collection Treatment of acute exacerbations in patients with Neuromyelitis Optica (NMO)Johns Hopkins Study start anticipated Q4 2012 Autoimmune Hemolytic Anemia (AIHA)AMC, Univ. of Amsterd
Slide 94: Neuromyelitis Optica (NMO)
Neuromyelitis Optica (NMO) 96 Inflammatory disease of the CNS that selectively attacks the optic nerves and spinal cord Prevalence: 1 – 3/100,000 Unique among the inflammatory demyelinating CNS diseases Associated with circulating IgG auto-antibodies against the astrocyte water channel protein aquap
Slide 95: Autoimmune Hemolytic Anemia (AIHA)
Autoimmune Hemolytic Anemia (AIHA) 97 Autoimmune disease involving auto-antibodies directed toward RBC surface antigens leading to accelerated destruction (hemolysis) Annual incidence: 1 – 3/100,0001 Two main types Warm AIHA: 70 – 80 % of cases (anti-RBC IgG > IgA, IgM) Cold AIHA (cold agglutinin sy
Slide 96: Update on ViroPharma Sponsored Studies
Update on ViroPharma Sponsored Studies 98 Antibody Mediated Rejection (AMR) in setting of renal transplant Approximately half of study cohort enrolled Anticipate study completion 4Q2013 Findings to be published Delayed Graft Function (DGF) reprioritized as a potential IIS study Laboratory study of P
Slide 97: Summary
Summary C1 Inhibitor: platform development opportunity Evolving science and greater understanding of complement-mediated disorders Emerging pre-clinical data informing potential new clinical targets More focused, mechanism-based approach Refinement of overall development strategy Broadening the hori
Slide 98: Subcutaneous Administration of C1 INH
Subcutaneous Administration of C1 INH Steven Gelone, PharmD Vice President, Clinical Development 100
Slide 99: ViroPharma 2012 Goals
VIROPHARMA 2012 GOALS PATIENTS LEGAL REGULATORY/QUALITY BD SALES & MARKETING MANAGED MARKETS TECH OPS CCOM MEDICAL AFFAIRS DEVELOPMENT FINANCE IT HUMAN RESOURCES VIROPHARMA INCORPORATED
Slide 100: Quote: Ralph Waldo Emerson
Do not go where the path may lead, go instead where there is no path and leave a trail. Ralph Waldo Emerson
Slide 101: Prevention of AE Attacks with Cinryze
Prevention of AE Attacks with CINRYZE has Transformed the Lives of Many Patients with HAE
Slide 102: Quote: Robert Frost
Two roads diverged in a wood, and I- I took the one less traveled by, And that has made all the difference. Robert Frost
Slide 103: Complacency Kills
Complacency Kills!!! “We shall have no better conditions in the future if we are satisfied with all those which we have at present.” -Thomas Edison
Slide 104: Why SC Administration of Cinryze?
Why SC Administration of CINRYZE? 1) More convenient option for HAE patients Route of administration Advantages Disadvantages Intravenous Precise control of dose and administration rate Rapid exposure Potential for reducing injection site reactions for irritating agents Minimal volume constraints (1
Slide 105: The Arithmetic of AE Attacks
Why SC Administration Of CINRYZE? The “Arithmetic” of AE Attacks Insufficient Concentration of C1 INH + “Trigger” = Increased Probability of an AE Attack “Vulnerable Period” 2) Decrease the “Vulnerable Period”
Slide 106: Treating vs Preventing an AE Attack
Time (hr) Dose administered IV SC It’s Important to Point Out That Treating An AE Attack is Different Than Preventing One. *For illustration purposes only U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450
Slide 107: Decrease the Vulnerable Period
“Vulnerable Period” Time (hr) IV SC Preventing AE Attacks.Decrease the “Vulnerable Period” *For illustration purposes only Infection Trauma, other Insufficient Concentration of C1 INH + “Trigger” U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450
Slide 108: Inhibition of auto-activation
Time (hr) “Ain’t It Like Most People, I’m No Different. We Love To Talk On Things We Don’t Know About.” The Avett Brothers Ziccardi, 1982; Windfuhr, 2005 Inhibition of auto-activation Prevention of AE attacks Spath, 1984; Cicardi, 1998 & unpublished; Hack, 2012 Abate an ongoing AE attack Hack et al.
Slide 109: Challenges of IV to SC
Going from IV to SC Presents a Few Challenges. Sc injection Molecules > 16kDa % Deposition at injection site % Peripheral lymphatic uptake Uptake of < 16 kDa Molecules into capillaries Degradation? Binding? Transport to central lymphatic ducts IV injection Thoracic blood vessel Impacted by: Protein
Slide 110: Methods to Address Challenges of SC Delivery
Potential Methods to Address The Challenges of SC Delivery “Shock and awe” dosing Optimize delivery system PH20 Micro-needle administration Optimize formulation
Slide 111: Significant Work Already Completed
We’ve Done A Significant Amount of Work Already. *completed Study 100* Single-dose Cinryze SC Healthy subject Functional C1-INH Change From Baseline (%) Concentration Functional C1 INH Activity (U/mL) 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 50 100 150 200 250 300 350 400 450 Time (h) Mean IV (N=25) Mean SC 10
Slide 112: Cinryze SC End-of-Phase 2 Meeting with FDA
CINRYZE SC- EoPh2 Meeting with FDA FDA provided feedback on completed studies, proposed study design, endpoints, safety database and commented on their desire for additional dose-ranging data *completed Cinryze SC Program April 2011 EoPh2 Meeting* Study 100* Study 200* Single-dose Cinyrze SC Healthy
Slide 113: Cinryze SC Program Timeline
WWVD??? *completed ; ^IND enabling Cinryze SC Program EoPh2 Meeting* April 2011 VPHM/ HALO Collaboration Initiated* May 2011 CINRYZE + PH20 Multi-dose in HAE pt Study 204* CINRYZE SC
Slide 114: Study 200/204 HAE Subjects: C1 INH Functional
CINRYZE Study 200/204 HAE-Subjects: C1 INH Functional 1000 U Time (hr) Dose administered U/mL 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 50 100 150 200 250 300 350 400 450 IV SC 1000 SC 1000 + PH20
Slide 115: Which of These Things Is Not Like The Other?
Which of These Things Is Not Like The Other?
Slide 116: Study 200/204 Additional Lessons Learned
CINRYZE Study 200/204 HAE-Subjects: Additional Lessons Learned CINRYZE SC ALONE CINRYZE + PH20 C1INH Function Plasma Concentration C1INH Function Plasma Concentration
Slide 117: Cinryze + rHuPH20 Program was Prioritized
CINRYZE + rHuPH20 Program was Prioritized Addition of rHuPH20 has the potential to improve: CINRYZE PK/PD profile Increased dispersion and absorption Reduces intra/intersubject variability Achieves physiologically relevant plasma concentrations associated with protection against HAE attacks Tolerabi
Slide 118: Baxter Complete Response Letter, July 2012
And Then On One Sunny Day in July 2012. Baxter receives Complete Response Letter from FDA for their HyQvia program Implications for the CINRYZE + PH20 program “Temporary clinical hold” on all clinical studies using the co-administration of hyaluorinidase for ‘life-span’ products within CBER while da
Slide 119: ViroPharma and Halozyme Clinical Development Update
And As You Probably Heard Earlier This Morning. VIROPHARMA AND HALOZYME PROVIDE UPDATE ON CLINICAL DEVELOPMENT OF SUBCUTANEOUS CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RECOMBINANT HUMAN HYALURONIDASE (rHuPH20) Exton, PA, September 21, 2012—Viropharma Incorporated (Nasdaq: VPHM) and Halozyme The
Slide 120: Cinryze SC Program: Next Steps
CINRYZE SC Program: Next Steps “Things turn out best for the people who make the best of the way things turn out.” -John Wooden
Slide 121: Cinryze SC Programs Next Steps
CINRYZE SC Programs Next Steps: The Best Offense is a Great Defense “Shock and awe” dosing Optimize delivery system PH20 Optimize formulation
Slide 122: Cinryze SC Programs: Next Steps
CINRYZE SC Programs: Next Steps Dose-ranging Long-term Prevention Study 30x Phase 1/2 Phase 3 Multi-dose in Healthy subject Study 102** CINRYZE + PH20 Single-dose in Healthy subject Study 101* Multi-dose in HAE pt Study 204^* Multi-dose in HAE pt Study 206** Long-term Prevention Study 300 *completed
Slide 123: Acknowledgements
Acknowledgements Collaborators Patients HAE Associations Clinicians and investigators Sanquin Halozyme ViroPharma Cinryze Team 125
Slide 124: An Update on Maribavir
An Update on Maribavir Stephen Villano, MD Vice President, Clinical Research & Development 126
Slide 125: Human Cytomegalovirus (CMV)
Human Cytomegalovirus (CMV) Beta herpesvirus Large genome Infection becomes latent 60-100% adults infected Close interaction with the immune system Can be fatal if over- immunocompromised Reddehase 2006 UL97 UL54 TRL TRS IRL IRS US UL 127
Slide 126: CMV Manifestations
CMV Manifestations Direct effects: CMV symptomatic viremia CMV invasive organ disease Indirect effects: Risk of other opportunistic infections Stem cell transplant (SCT): risk of graft versus host disease (GVHD) Solid organ transplant (SOT): risk of graft organ rejection / graft loss Survival disadv
Slide 127: Current Anti-CMV Drugs and Toxicity
Renal Toxicity, Seizures Drug Form. CMV Indication Toxicity ganciclovir IV Treatment of CMV retinitis in immunocompromised patientsPrevention of CMV disease in transplant recipients at risk Bone marrow suppression, carcinogenic, teratogenic ganciclovir PO Prevention of CMV disease in solid organ tra
Slide 128: Maribavir: A Novel Anti-Viral Drug
Chemical class: benzimidazole Orally bioavailable Unique mechanism: Inhibit viral encapsidation Inhibit nuclear egress of viral particles Unlike other anti-CMV agents, maribavir does not affect the UL54 CMV DNA polymerase Maribavir has in vitro activity against strains of CMV resistant to other anti
Slide 129: Mechanism of Action
Mechanism of Action UL97 (CMV) DNA elongation DNA packaging Capsid egress Protein kinase GCV UL97 (CMV) GCV-P UL54 Viral DNA replication Chain termination DNA polymerase Protein kinase Ganciclovir Maribavir
Slide 130: Maribavir for CMV Treatment
US Emergency-IND(E-IND) a EUName Patient Program (NPP) b Population studied Resistant / Refractory CMV Resistant / Refractory CMV Number with data 6 9 SCT / SOT 1 / 5 3 / 6 Known resistance mutations to GCV or FOS 4 (67%) 6 (67%) Virologic response CMV Undetectable:4 (67%) CMV ? ^1.5 log or undetect
Slide 131: Phase 2 Dose Ranging Studies in Transplant Recipients
Phase 2 Dose Ranging Studies in Transplant Recipients EU: first line treatment of CMV viremia US: treatment of resistant/ refractory CMV disease Study Number 1263-203 1263-202 Regimens MBV 400 mg BID MBV 400 mg BID Regimens MBV 800 mg BID MBV 800 mg BID Regimens MBV 1200 mg BID MBV 1200 mg BID Regim
Slide 132: EU Phase 2 Study Preliminary Virology Data
EU Phase 2 Study (1263-203) Preliminary Virology Data Number with data available through Week 2 10 SCT / SOT 8 / 2 Virologic response CMV Undetectable:10 / 10 (100%) Quant. Limit 200 copies/mL NOTE: shown are interim data only; study is ongoing 134
Slide 133: Maribavir: Next Steps
Maribavir: Next Steps On-going Phase 2 dose ranging studies in transplant recipients Phase 1 studies / higher doses (in concert with dose finding) Discussion with Regulatory agencies re: pivotal design Pivotal Studies ? NDA EU: first line treatment of CMV viremia US: treatment of resistant/ refracto
Slide 134: Transplantation: Numbers
Transplantation: Numbers Total transplants per year(all ages) US EU SCT (Allogeneic) 7,012 a 13,345 b SOT 28, 537 c 30,448 d Kidney 16,813—Liver 6,342—Heart 2,322—Lung 1,822—Other 1,238—a) CIBMTR 2009; b) EBMT 2010; c) OPTN 2011; d) estimate from multiple registries 136
Slide 135: Patient Population Assumptions
Patient Population Assumptions 100 patients 25% MBV 60 Viremic 70% responding 14 pts. 31 pts. 12 patients 90% switch to MBV 16 patients 50% intolerant, switch to MBV 30% not responding 45 pts. 75% (v)GCV SOT: 100 patients 25% MBV 40 Viremic 70% responding 9 pts. 21 pts. 8 patients 90% switch to MBV
Slide 136: Conclusions
Conclusions CMV continues to be the most important transplant infection, with direct and indirect adverse effects Current therapy for CMV is limited by toxicity that can restrict use Maribavir, at higher doses, has been shown to decrease viral load in preliminary evaluations of CMV-infected transpla
Slide 137: VP-20621 Non-toxigenic C. difficile
VP-20621 Non-toxigenic C. difficile Colin Broom, MD Vice President, Chief Scientific Officer 139
Slide 138: VP-20621 – For the Prevention of Recurrence of CDI
VP-20621 – For the Prevention of Recurrence of C. difficile Infection (CDI) CDI – An Overview The Problem of CDI Recurrence Clinical Study Results to Date Summary & Conclusions 140 For internal use only—CONFIDENTIAL
Slide 139: CDI Overview
CDI Overview 141 Spore-forming, anaerobic, gram-positive bacterium Causes gastrointestinal infections resulting in diarrhea and colitis Severity ranges from mild colitis to toxic megacolon and death Leading cause of healthcare-associated infectious diarrhea in US Rivals methicillin-resistant Staphyl
Slide 140: Treatment is Effective but has Limitations
Treatment is Effective but has Limitations 142 Standard of care is oral metronidazole or vancomycin, with fidaxomicin a recent introduction All are associated with recurrence No approved therapy for prevention of recurrence Current practice: Repeated antibiotic therapy Other non-approved agents or p
Slide 141: Recurrence Rate Increases after First CDI Episode
Recurrence Rate Increases after First CDI Episode 20% 45% 65% 1. Aslam S, et al. Lancet Infect Dis. 2005;5:549-557. 2. McFarland LV, et al. Am J Gastroenterol. 2002:97:1769-1775. 3. McFarland LV, et al. JAMA. 1994;271:1913-1918. 0% 10% 20% 30% 40% 50% 60% 70% After first episode 1 After first recurr
Slide 142: Unmet Medical Need is Recognized
Unmet Medical Need is Recognized CDI Competitive Landscape Antibiotics with narrower spectrum May reduce but will not prevent recurrence No difference in recurrence rate with the hyper-virulent BI/NAP1/027 strain Monoclonal antibodies to Toxin A & B Vaccine approach to prevention 144
Slide 143: VP-20621 May Address this Unmet Medical Need
VP-20621 May Address this Unmet Medical Need VP-20621 is a formulation of spores of a specific, naturally occurring non-toxigenic strain of C. difficile Can colonize the GI tract of susceptible individuals Colonization may prevent CDI, based on animal and epidemiological studies 145
Slide 144: NTCD Phase 1 Study Design
NTCD Phase 1 Study Design Safety and Tolerability of an Oral Suspension of VP-20621, Spores of a Non-Toxigenic C. difficile Strain, in Healthy Older Subjects Well tolerated with single and repeat doses: 1x104, 1x106, or 1x108 spores (or matching placebo) Colonization of all subjects pre-treated with
Slide 145: 20621-200 Phase 2 Study
20621-200 A Phase 2 Randomized, Double-Blind, Placebo- Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) in Adults Previously Treated for CDI 147
Slide 146: 20621-200 Study Design
Screening (Up to 28 days) Study Drug Administration (14 Days) Follow-Up Vanco or Metro 10-21 days; CDI Resolves CDI Onset Randomize to start study drug after end of Vanco/Metro 107 QD x 7d 107 QD x 14d 104 QD x 7d F/U to Week 26 Placebo Placebo Placebo Key timepoint for efficacy assessments 20621-20
Slide 147: Study Objectives
Study Objectives Evaluate the safety and tolerability of VP-20621 Determine colonization of the GI tract in patients treated for CDI Select a dosing regimen based on colonization data Preliminary information on the prevention of recurrence
Slide 148: Achievement of Study Objectives
Achievement of Study Objectives Interim data in 106 of target 240 patients Well tolerated, no safety issues identified Ability to colonize clearly demonstrated Good data on dose and duration of therapy Limited but informative data on disease recurrence
Slide 149: 20621-200: Interim Subject Characteristics
Interim N 106 Age (yrs) Median (range) 59 (18-94) ^65 39% Female / Male 63% / 37% Inpatient / Outpatient 20% / 80% Primary CDI 81% Initial CDI Treatment Metronidazole 61% Oral vancomycin 24% Both 15% 20621-200: Interim data subject characteristics
Slide 150: Preliminary C. difficile Stool Culture Data
Based on 106-subject interim analysis 20621-200 Preliminary C. difficile Stool Culture Data Cx + Tox+ Cx+ Tox—(NTCD) Placebo (n=20-22 subjects per visit) 100% 80% 60% 40% 20% 0% D1 D8 D15 W3 W6 0% 0% 0% 0% 15% 18% 62% 67% 70% 40% Study Visit NTCD 104 x 7d (n=27-28 subjects per visit) 100% 80% 60% 40
Slide 151: 20621-200 Preliminary CDI Recurrence Data
20621-200 Preliminary CDI recurrence data Based on 106-subject interim analysis PBO 104 x 7d 107 x 7d 107 x 14d ITT-S Subjects 23 29 26 28 Subjects with: CDI recurrence No recurrence occurred in patients colonized with VP20621
Slide 152: Summary and Conclusions from Interim Data
Summary and Conclusions from Interim Data VP-20621 was well tolerated with no safety issues identified Limited recurrence data has been informative Eight of the 10 patients with recurrent disease in the VP-20621 treated groups had a toxigenic strain at Day 1 and/or Day 8 suggesting that earlier trea
Slide 153: Financial Update / Guidance
Financial Update / Guidance Charles Rowland Chief Financial Officer 155 This presentation includes non-GAAP forecasted gross margins. We believe that presentation of forecasted non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors.
Slide 154: ViroPharma Outlook
ViroPharma Outlook 156 Significant short to midterm sales growth Growth from existing products Geographic expansion Not pipeline dependent Efficient operating model requiring lower R&D and SG&A spend Generating greater GAAP and Non-GAAP returns Net Income EPS Efficient use of Cash Lower risk busines
Slide 155: Product Outlook
Product Outlook Estimate of Commercial Potential Cinryze® – HAE IV only US & Europe Sustained growth in demand—driven by consistent patient adds and dosing rates >$700M Europe – Buccolam,® Cinryze, Plenadren®(Cinryze also included in guidance above) 2012 and 2013 are key launch years for all three E
Slide 156: Marketed Products Expected to Contribute ~20% CAGR
Marketed Products Expected to Contribute Approximately 20% CAGR through 2015 158 $700—$800 $0 $250 $500 $750 $1,000 2012 2015 Guidance Range Net Sales Net Sales ($ millions)
Slide 157: Europe Expected to Become a Larger Share of the Business
Europe Expected to Become a Larger Share of the Business and a Significant Contributor to Top Line Growth 159 2012 Sales Breakdown 2015 Sales Breakdown EU Sales 5% US Sales 95% Row Sales<1% EU Sales ~30% US Sales ~70%
Slide 158: Current Pipeline
Current Pipeline 160 2012 2013 2014 2015 2016 2017 Formulation Development C1 INH – SC Expansion Plenadren – US Pipeline Maribavir (CMV) VP 20629 (Friedreich’s Ataxia) VP 20261 (Rec. C-Diff) Oral Budesonide (EoE) Cinryze (AMR) C1 Esterase (New Uses) C1 Recombinant Phase 2 Phase 3 Approval Path forwa
Slide 159: Pipeline Provides Commercial Potential Upside
ViroPharma Pipeline Provides Commercial Potential Upside 161 Pipeline opportunities primarily focused on orphan indications Potential to contribute meaningfully to longer-term revenue growth Other components of upside: Plenadren US VP-20629 (Friedreich’s Ataxia) Oral Budesonide (EoE) Recombinant C1-
Slide 160: Disciplined Expense Management
Disciplined Expense Management with Targeted Investments to Drive Growth 162 Gross Margin Ex-Vancocin margins have remained consistentExpected to improve slightly in near-term Streamlined operating model requiring lower R&D and SG&A spend R&D Spend is focused on development onlyTargeted toward futur
Slide 161: Revenue Drivers and Expense Management Drive Earnings Power
Revenue Drivers and Expense Management Translates to Significant Earnings Power Tangible near-term revenue growth Cinryze® new patient growth and acceleration in Europe Plenadren® and Buccolam® launch execution Targeting future lower operating costs and lower R&D spend due to development focus Inves
Slide 162: Disciplined and Efficient Capital Management
Commitment to Disciplined and Efficient Capital Management ViroPharma is committed to being good stewards of investor capital $82M share repurchase in Q3 2012 (3.1m Shares) Strong near-term liquidity with $390M in cash and $200M in revolver capacity Returned $323M to shareholders in 2011 – 2012 (14.
Slide 163: Our Deal History
Our Deal History 165 ($ millions) Upfront Payment Milestones Total Deal Value Peak Sales Potential Marketed Products Vancocin 116.0 51.1 167.1 289.0 Cinryze 453.1 92.1 545.2 >700.0 Plenadren 35.0 88.0 123.0 >200.0 * Buccolam 14.5 15.8 30.3 90.0 Pipeline Halozyme 9.0 47.0 56.0 Meritage 12.5 252.4 264
Slide 164: 2015 Outlook
2015 Outlook A Growth Story 166 Category Estimate of Future Opportunity ($ in millions) Total Company Net Sales $700M—$800M R&D and SG&A Combined $270M—$320M Effective Tax Rate ~32% Earnings Growth Differentiated
Slide 165: Conclusions
Conclusions Significant short to midterm sales growth Growth from existing products Geographic expansion Not pipeline dependent Efficient operating model requiring lower R&D and SG&A spend Generating greater GAAP and Non-GAAP returns Net Income EPS Efficient use of Cash Lower risk business developme
Slide 166: Quote: Ralph Waldo Emerson
Do not go where the path may lead, go instead where there is no path and leave a trail. Ralph Waldo Emerson
Slide 167: Questions & Answers
——| Avligrunrn Questions & Answers 169